Trial Profile
A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 May 2020
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Fragile X syndrome; Mental retardation
- Focus Therapeutic Use
- Acronyms FAB-C
- Sponsors Zynerba Pharmaceuticals
- 26 May 2020 New two-year data from open label extension published in the Zynerba pharmaceuticals Media Release.
- 26 May 2020 According to an Zynerba pharmaceuticals media release, new two-year data from open label extension of this Phase 2 FAB-C Trial in Patients with Fragile X were presented as a poster at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session.
- 09 Mar 2020 According to a Zynerba pharmaceuticals media release, data will be presented at the American Academy of Neurology (AAN) 2020 Annual Meeting.